Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016', provides an overview of the Resistant Pseudomonas aeruginosa Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections
- The report reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Resistant Pseudomonas aeruginosa Infections therapeutics and enlists all their major and minor projects
- The report assesses Resistant Pseudomonas aeruginosa Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Resistant Pseudomonas aeruginosa Infections Overview 7
Therapeutics Development 8
Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Overview 8
Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis 9
Resistant Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies 10
Resistant Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 11
Resistant Pseudomonas aeruginosa Infections - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Resistant Pseudomonas aeruginosa Infections - Products under Development by Companies 14
Resistant Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes 16
Resistant Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 17
Achaogen Inc. 17
AstraZeneca Plc 18
Biolytics Pharma 19
CSA Biotechnologies LLC 20
LegoChem Biosciences, Inc 21
Melinta Therapeutics, Inc 22
Phico Therapeutics Limited 23
Shionogi & Co., Ltd. 24
Zambon Company S.p.A. 25
Resistant Pseudomonas aeruginosa Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ACHN-975 Prodrug - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CSA-13 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
G-10 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
IMT-504 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
LCB-010200 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LCB-100200 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
PT-3.33 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
RXP-763 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RXP-766 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
RXP-770 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
RXP-792 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
RXP-793 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
RXP-808 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
RXP-873 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
S-649266 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ZP-046 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Resistant Pseudomonas aeruginosa Infections - Dormant Projects 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2016 8
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 (Contd..1) 15
Products under Investigation by Universities/Institutes, H2 2016 16
Resistant Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc., H2 2016 17
Resistant Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2016 18
Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2016 19
Resistant Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC , H2 2016 20
Resistant Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016 21
Resistant Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016 22
Resistant Pseudomonas aeruginosa Infections - Pipeline by Phico Therapeutics Limited, H2 2016 23
Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H2 2016 24
Resistant Pseudomonas aeruginosa Infections - Pipeline by Zambon Company S.p.A., H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H2 2016 60